Antiretroviral Treatment of US Children With Perinatally Acquired HIV Infection: Temporal Changes in Therapy Between 1991 and 2009 and Predictors of Immunologic and Virologic Outcomes
Russell B. Van Dyke(Tulane University), George R. Seage(Unknown), Sandra Burchett(Harvard University), Jennifer S. Read(Foundation for Human Potential), Kunjal Patel(Cancer Research And Biostatistics), George K. Siberry(Columbia University Irving Medical Center), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Miriam C. Chernoff(Cancer Research And Biostatistics), Stephen A. Spector(University of California San Diego)
Cited by 78
Related Papers
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1–Infected Women and Prevention of Perinatal HIV-1 Transmission
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2002|896
Lymphocyte subsets in healthy children from birth through 18 years of age
|Journal of Allergy and Clinical Immunology|2003|828
Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant
|New England Journal of Medicine|1996|817